SCHEMBL4873370

SCHEMBL4873370

Cc1cc(CN2CCC(N(C)S(=O)(=O)c3ccc(Nc4nccc(Nc5ccc(F)c(F)c5)n4)cc3)CC2)no1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.41
CDK4 P11802 2/20 0.41
CDK2 P24941 2/20 0.41
CCNE1 P24864 1/20 0.41
ACVR1 Q04771 1/20 0.39
IKBKB O14920 1/20 0.38
CHUK O15111 1/20 0.38
JAK2 O60674 4/20 0.38
BRD4 O60885 2/20 0.38
JAK3 P52333 2/20 0.37
CA2 P00918 3/20 0.36
CA9 Q16790 2/20 0.36
CA1 P00915 1/20 0.36
MAPT P10636 1/20 0.36
CSF1R P07333 2/20 0.35
TYK2 P29597 1/20 0.35
ULK2 Q8IYT8 1/20 0.35
TBK1 Q9UHD2 1/20 0.35
CDK6 Q00534 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4623364 0.95 IGF1R (0.41) IGF1RCDK4CDK2CCNE1ACVR1
SCHEMBL14020141 0.92 IGF1R (0.39) IGF1RCDK4CDK2CCNE1ACVR1
SCHEMBL14020121 0.88 CDK2 (0.40) IGF1RCDK4CDK2CCNE1ACVR1
SCHEMBL14020104 0.88 IKBKB (0.41) IGF1RCDK4CDK2CCNE1ACVR1
SCHEMBL4880324 0.86 CDK2 (0.39) CDK4CDK2CCNE1ACVR1IKBKB
SCHEMBL14020097 0.85 ACVR1 (0.41) CDK4CDK2CCNE1ACVR1IKBKB
SCHEMBL14020086 0.84 IGF1R (0.42) IGF1RCDK4CDK2CCNE1IKBKB
SCHEMBL4876612 0.84 HTR2A (0.51) CDK4CDK2CCNE1IKBKBCHUK
SCHEMBL4880639 0.84 CDK4 (0.42) CDK4CDK2CCNE1ACVR1IKBKB
SCHEMBL4883653 0.84 SCN8A (0.40) CDK4CDK2CCNE1ACVR1IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed
WO-2007006926-A2 NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE IGF1R 1514/4885CDK4 54/4885CDK2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.